Principles and Structure of a Research Protocol Anthony Harries The Union, Paris, France.

Slides:



Advertisements
Similar presentations
DOTS/ DOTS PLUS IMPLEMENTATION AND INTEGRATION Vaira Leimane State Centre of Tuberculosis and Lung Diseases of Latvia Paris, October, 28.
Advertisements

The Roadmap to Successful Xpert Implementation - 37 steps -
Module 11: Community TB Care Image source: Pierre Virot, World Lung Foundation.
Improving and Harmonizing Operational Research in Tuberculosis Anthony D Harries The Union, Paris, France.
How to Write a Research Proposal Detroit Medical Center Nursing Research Council.
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
World Health Organization TB Case Definitions
1 Project planning and management 4 scenarios in comparison Dr. Birgit Greiner Senior Lecturer.
Module 9 Part A: Monitoring and Evaluation *Image courtesy of: World Lung Foundation.
Health service utilization by patients with common mental disorder identified by the Self Reporting Questionnaire in a primary care setting in Zomba, Malawi.
Integrated Monitoring and Evaluation of HIV Programs in Malawi Dr Andreas Jahn 1,2 1 Dept. for HIV and AIDS, MOH, Malawi 2 I-TECH Malawi.
International Standards of Tuberculosis Care Implementation by Pulmonologists in Private Practice in Jakarta E. Burhan 1, M. A. Nawas 1, D. Kusumo Sutoyo.
Factors Associated with Interruption of Treatment Among Pulmonary Tuberculosis Patients in Plateau State, Nigeria, 2011 Luka M. Ibrahim 1, P. Nguku 1,
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs Using the Compendium to Plan for Monitoring and Evaluation of NTPs.
Indicators, Data Sources, and Data Quality for TB M&E
Predictors of Multidrug Resistant Tuberculosis Among Adult Tuberculosis Patients in Saint Peter Hospital, Addis Ababa, Ethiopia: Case control study.
Impact of Side Effects of Antipsychotics on Attitude and Adherence to Treatment among Adult Psychiatric Outpatients at Mathari Hospital in Kenya Defense.
OPERATIONAL RESEARCH What, Why and How? Dr. Rony Zachariah MD, PhD
Tuberculosis in the UK 2013 report
BY ZIONE MAJAWA CHINOKO St. John of God College of Health Sciences, Mzuzu.
Culture Conversion and Self- Administered Therapy in Privately Managed Tuberculosis Patients Melissa Ehman MPH, Jennifer Flood MD MPH, Pennan Barry MD.
Evaluation Methods.
RNTCP: DOTS Expansion and plans for DOTS-Plus
DETERMINANTS OF FORECAST ACCURACY FOR PAEDIATRIC ANTIRETROVIRAL DRUGS IN KENYA NJOGO, SUSAN MUTHONI GICHUKI (U51/82556/2012)
Increasing HIV treatment for TB patients – thinking out of the box Anthony D Harries, The Union Paris, France.
The Union/ MSF Model for sustainable operational research The Union, Paris, France MSF, Brussels, Belgium.
Outcomes among patients treated for tuberculosis in Limpopo Province, South Africa, Mmakgotso Pilane, Lazarus Kuonza, Eric Maimela.
5 DECEMBER 2012 PRESENTER: AS SESING MCWH MANAGER(FSDOH)
Denise F. Johnson, MPH, MBA LaShaunda L. Malone, MSPH Catherine M. Stein, PhD American Public Health Association Meeting November 5, 2013 Boston, MA. The.
RISK ADJUSTMENT CODING
Monitoring and Evaluation Module 12 – March 2010.
Extrapulmonary Site 2 :_____________________ Name (surname, first name) Age (in years) Sex F Alternative address Physical Address (in full) M INTERIM TUBERCULOSIS.
DOTS Expansion: Monitoring Drugs Leopold Blanc TBS, Stop TB WHO, Communicable Diseases.
Role of private pharmacies in TB control in Egypt, 2009 Principal investigators Dr.Sherry Victor / NTP Logistic and DR-TB officer Dr. Magdy Fawzy/ Research.
Orientation on HIV care and ART Recording and Reporting System.
Sources of Limited Access to Treatment High Cost of Treatment Lack of Pilot Projects Lack of Evidence Lack of Policy Lack of Demand.
Unit 12: Reporting & Recording Botswana National Tuberculosis Programme Manual Training for Medical Officers.
PREVALENCE OF MDR-TB AMONGST PATIENTS WITH HIV AND TB CO- INFECTION SEEN AT THE DOTS CLINIC OF N.I.M.R., LAGOS, NIGERIA. Enya V.N.V, Onubogu C.C., Wahab.
DOTS-PLUS IN TANZANIA: PREPARATION PHASE Global DOTS Expansion Working Group Meeting, Paris: 28 October 2004 NTLP - MOH Prepared by: Dr. S. M. Egwaga NTLP.
Task Shifting in Malawi around delivery of antiretroviral therapy Anthony D Harries “The Union” Paris, France.
Monitoring Process of the National TB Control Program (NTP) in the Philippines Anna Marie Celina G. Garfin, MD Medical Specialist IV National Center for.
Implementing the revised TB/HIV indicators and data harmonisation at country level Christian Gunneberg MO WHO Planning workshop to accelerate the implementation.
The revised TB/HIV indicators and update on the process of harmonization Christian Gunneberg MO WHO The 14th Core Group Meeting of the TB/HIV Working Group.
Extrapulmonary Site 2 :_____________________ TUBERCULOSIS TREATMENT CARD BOTSWANA NATIONAL TUBERCULOSIS PROGRAMME Date RegisteredIN ToOUT RegisteredIN.
MATERIAL & METHODS SECTION PREPARATION (IN THE HEALTH RESEARCH PROPOSAL) DR. HAYFAA A. WAHBI ASSISTANT PROFESSOR, CHAIR OF EBHC & KT COLLEGE OF MEDICINE.
OPERATIONAL RESEARCH What, Why and How Anthony D Harries The Union, Paris, France London School of Hygiene and Tropical Medicine, UK
From operational research to policy and practice The Union, Paris, France MSF, Brussels, Belgium.
Operational research to Policy and Practice: examples Anthony D Harries, The Union, Paris, France London School Hygiene & Tropical medicine.
1 Identifying Contribution of Community-based DOTS in Treatment Outcome of TB Patients in Four Provinces of Afghanistan Qader, Ghulam MD, DPH, MPH Senior.
Developing a Research Question and Writing a Proposal GH531/ Epi
Roundtable. Detection and treatment of TB Andrew Black.
Tuberculosis in Children: Treatment and Monitoring Module 10B - March 2010.
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs.
CRITICALLY APPRAISING EVIDENCE Lisa Broughton, PhD, RN, CCRN.
Improving HIV care and support service performance in Côte d’Ivoire M. N’goran 1 ; S. Ramachadran 2 ; J. Essombo 1 et al M. N’goran 1 ; S. Ramachadran.
Priscilla Tsondai, Lynne Wilkinson, Anna Grimsrud, Angelina Trivino,
Monitoring and Evaluation: A Review of Terms
TB- HIV Collaborative activities in Romania- may 2006 status
February 03, 2011 Daniel G. Datiko
Daffodil International University (DIU), Dhaka Bangladesh
R Nagar 1, Debashish Kundu2, S Chandra2 , A Khanna1
The role of the community in TB control
FRANCIS GAUSI and THOMAS NYIRENDA MALAWI.
monitoring & evaluation THD Unit, Stop TB department WHO Geneva
Monitoring of Antiretroviral therapy (ART)delivery by Regional Tuberculosis Officers (RTO) in Malawi: Rhehab Chimzizi Anthony Harries Edwin Libamba Maxwell.
Indicators, Data Sources and Data Quality for TB M&E
Routine Counselling and HIV testing (CT) for TB patients in Malawi: Rhehab Chimzizi TB-HIV Programme officer National TB Control Programme-Malawi.
Fabio Scano IUATLD Conference Paris, 2003
5th edition NTP MANUAL OF PROCEDURES Reporting
Preventing recurrent TB in high HIV-prevalent areas
Presentation transcript:

Principles and Structure of a Research Protocol Anthony Harries The Union, Paris, France

BASIC STRUCTURE Background and rationale to study Aim and objectives (the research question) Methods (includes ethics submission) Budget and time lines Justification

Background and Rationale Country / context in which study is to be done The problem and what is known about it Are there knowledge gaps? Will this study fill those knowledge gaps?

Aim and Objectives Aim is broad Objectives are more specific

For example: (1) AIM To document the management and outcome of new smear-positive Pulmonary TB patients who fail first line treatment in Malawi

For example: (2) Specific Objectives are to determine:- 1. The number of new smear-positive PTB patients who failed treatment 2. The management of patients who failed 3. Their treatment outcomes on Re-Rx regimen 4. The culture and drug sensitivity results of those who failed and in relation to treatment outcomes

Methods Study design (descriptive, case-control, cohort) Setting – general and study site Participants (and study period) Data variables to be collected: –exposure and outcome variables –data collection instrument (when data collected) –data validation Sources of data Analysis and statistics (sample size, if needed) Ethics approval

Recurrent Tuberculosis in Malawi

BACKGROUND: NTP in Malawi (1) Model “DOTS” Programme Management by District TB officers Excellent Monitoring and Evaluation, using Registers and quarterly cohort reporting 27,000 cases of TB registered per annum HIV-prevalence in TB patients = 70%

The problem and rationale (2) Between 1987 to 1999: % Patients registered nationally with Relapse smear- positive PTB in Malawi declined from 6% to 3% No reported cases of recurrent smear-negative TB BUT HIV-prevalence in TB patients increased from 30% to 70% Research literature from Africa (4 studies) showed that recurrent TB increases as HIV-prevalence increases

Annual TB recurrence HIV+veHIV-ve Zaire18%6% (Perriens et al 1991) Kenya17% 0.5% (Hawken et al 1993) Zambia22%6% (Elliott et al 1995) S.Africa16%6% (Sonnenberg et al 2001)

HIV and TB in Malawi YearSiteNo. TB% HIV-positive 1986Zomba Mzuzu Blantyre Zomba Malawi

The research question: Is the Malawi NTP missing recurrent tuberculosis under routine programme settings?

AIM of the Study To determine whether patients who have been registered as “New TB” been previously diagnosed and treated as relapse smear-positive Pulmonary TB and recurrent smear-negative TB?

METHODS

Design This will be a cross-sectional study involving a structured interview of TB patients [other study designs include descriptive, cross- sectional, case-control, and cohort – either prospective or retrospective]

Setting and site visits General: Malawi is a small country in Africa with high HIV and TB burden. There is a country-wide DOTS Programme and all patients spend the first two months of TB treatment in hospital receiving initial phase therapy Site visits: All hospitals in the country that register and treat patients with TB will be visited. These include 3 central hospitals, 22 district hospitals and 18 mission hospitals Timing of the visits: These hospitals will be visited between January and June 1999 as part of the routine NTP supervision

Participants (patients) All patients who are in hospital receiving treatment during the initial phase and who have been registered as “New TB” will be interviewed using a structured questionnaire Patients will be identified by going round the TB wards (all patients are admitted to TB wards) in a set fashion and this will include all patients in their beds Patients not in their beds at the time will not be interviewed: a record will be made of TB registration number, age, sex, and type of TB

Variables, data collection and validation Variables to be collected include: -TB registration no., age, sex, type of TB, previous history of TB Those with previous history of TB will be asked: when, what type of TB, was treatment completed Data to be collected into a structured questionnaire Validation of data on previous TB will be done using TB identity cards wherever possible

Sources of data: All patients in their TB beds will be interviewed Patients who are out of the TB ward and cannot be traced will not be included [however, their age, sex and type of TB will be listed and compared with those in bed to ensure the two groups are similar]

Analysis and statistics Data will be entered into EPI-INFO software X 2 test will be used to compare differences in proportions between groups (odds ratios with 95% confidence intervals) Differences at 5% level (p < 0.05) to be regarded as significant

Sample size Not calculated because this is a national study involving all patients in hospital at the time of the visit

Ethics approval Study to be approved by the TB programme management group Ethics approval to be obtained from the Malawi National Health Science Research Committee

BUDGET Research ActivityCosting (USD$) Two NTP operational research officers for hotel accommodation and daily perdiems 450 Stationary50 TOTAL500 Research piggy-backed onto routine supervision and therefore less costly

JUSTIFICATION If hypothesis is correct, and previously treated patients are incorrectly registered as “new patients”, then:- Incorrect treatment is administered Incorrect data are reported to WHO We need to find out why and educate District TB Officers about proper management

Results Type of TBRegistered as “New”Previous TB All types (8%) Sm+ve PTB74634 (5%) Sm-ve PTB28240 (14%) EPTB22620 (9%) Trans Roy Soc Trop Med Hyg 2000; 94:

Only 9 out of 94 previous episodes were validated with the patient producing an Identity card

Analysis Compared to patients with smear-positive PTB, a previous episode of TB was significantly more common in :- patients with smear-negative PTB (OR 3.5, 95% CI , p < 0.001) patients with EPTB (OR 2.0, 95% CI , p < 0.05)

Interpretation of Study Patients with relapse TB and recurrent TB were incorrectly registered under routine programme settings as “new patients” This mistake was more common in patients with smear-negative PTB and EPTB The reasons for these mistakes were not identified

What next? Results and implications of incorrect recording discussed with NTP staff at the annual NTP seminar held 3 months later Central Unit prepared interim guidelines about diagnosis and management of recurrent TB Guidelines were incorporated into revised National TB Manual about one year later

A similar study was conducted from Jan-Jun 2000 Same aim: to determine whether patients registered with “new smear-negative PTB or new EPTB” were correctly diagnosed Same methodology as the study in 1999 except the focus was on smear-negative PTB and EPTB

Operational Research Jan-Jun 2000 Type of TB Registered “New” Previous TB sm-ve PTB (5%) EPTB213 2 (1%) [ a big improvement on the previous year ] Trans Roy Soc Trop Med Hyg 2001; 95:

How did this operational research impact on the Malawi National TB Control Programme?

Malawi TB case notifications YearTotal TBNew TBRecurrent TB (3%) (3%) Interventions to improve correct recording of TB cases (8%) (9%) (11%) (12%) Recurrent TB = relapse, failure, treatment after default, recurrent sm-ve TB